Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Jennifer Kleponis, Richard Skelton, Lei Zheng

Research output: Contribution to journalReview articlepeer-review

Abstract

Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor-infiltrating effector T cells. Cancer vaccines may prime patients for treatments with immune checkpoint inhibitors by inducing effector T-cell infiltration into the tumors and immune checkpoint signals. The combination of cancer vaccine and an immune checkpoint inhibitor may function synergistically to induce more effective antitumor immune responses, and clinical trials to test the combination are currently ongoing.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalCancer Biology and Medicine
Volume12
Issue number3
DOIs
StatePublished - Sep 1 2015

Keywords

  • Cancer vaccine
  • Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
  • Immune checkpoint
  • Immunotherapy
  • Programmed cell death ligand-1 (PD-L1)
  • Programmed death-1 (PD-1)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this